Relief Therapeutics Holding (XSWX:RLF) YoY EBITDA Growth : -66.97% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Relief Therapeutics Holding's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -66.97%.

Relief Therapeutics Holding's EBITDA per Share for the six months ended in Dec. 2023 was CHF-3.69.

Relief Therapeutics Holding YoY EBITDA Growth Historical Data

The historical data trend for Relief Therapeutics Holding's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding YoY EBITDA Growth Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-4,384.31

55.36

-256.42

-27.45

-98.21

Relief Therapeutics Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															21.58	-38.98	-17.46	-130.72	-66.97

Relief Therapeutics Holding YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Relief Therapeutics Holding's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-9.193	-	-4.638)	/	\| -4.638 \|
=	-98.21 %

Relief Therapeutics Holding's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-3.685	-	-2.207)	/	\| -2.207 \|
=	-66.97 %

Relief Therapeutics Holding YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (XSWX:RLF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFTF:USA RLFz:UK

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (XSWX:RLF) Headlines

No Headlines